NEW YORK, NY / ACCESSWIRE / May 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX). Investors who purchased MacroGenics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MGNX.
Investigation Details:
MacroGenics revealed its clinical trial update as part of its recent earnings report, admitting that five patients had died during its TAMARACK study. Following this news, MacroGenics stock dropped over 70% on May 10, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased MacroGenics securities, you can assist this investigation by visiting the firm's site: bgandg.com/MGNX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original
press release on accesswire.com
